PoliticalRepoPoliticalRepo

Person

Official portrait of Marc Veasey

Marc Veasey

United States · Official source

Records

2,681 records where Marc Veasey is listed as a sponsor, author, or other actor. Search with topics and years

Bill· HRH.R. 9944 (119th)referred

TPS Review Act

United States · United States Congress · 23 July 2026

Bill· HRH.R. 9432 (119th)referred

LIFT the BAR Act

United States · United States Congress · 24 June 2026

Bill· HRH.R. 9437 (119th)referred

Right to Vote Act

United States · United States Congress · 24 June 2026

Bill· HRH.R. 8907 (119th)referred

IMPACT to Save Moms Act

United States · United States Congress · 19 May 2026

Innovative Maternal Payment and Coverage To Save Moms Act or the IMPACT to Save Moms Act This bill requires the Centers for Medicare & Medicaid Services to establish the Perinatal Care Alternative Payment Model Demonstration Project through FY2031 to allow states to test payment models for maternity care, including postpartum care, under Medicaid and the Children's Health Insurance Program (CHIP). 

Bill· HRH.R. 8811 (119th)referred

Moms Matter Act

United States · United States Congress · 14 May 2026

Bill· HRH.R. 8317 (119th)referred

Tech to Save Moms Act

United States · United States Congress · 15 April 2026

Bill· HRH.R. 8261 (119th)referred

Chronic Care Management Improvement Act of 2026

United States · United States Congress · 14 April 2026

Chronic Care Management Improvement Act of 2026 This bill eliminates cost-sharing for chronic care management services under Medicare.

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Bill· HRH.R. 8074 (119th)referred

Kira Johnson Act

United States · United States Congress · 25 March 2026

Bill· HRH.R. 8080 (119th)referred

Data to Save Moms Act

United States · United States Congress · 25 March 2026

Bill· HRH.R. 8055 (119th)referred

Extending WIC for New Moms Act

United States · United States Congress · 24 March 2026

Extending WIC for New Moms Act This bill amends the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) to extend the eligibility periods for breastfeeding and postpartum women. Specifically, a state program may elect to certify a breastfeeding woman for up to 24 months (currently 1 year) postpartum. The bill also expands the eligibility period for postpartum women to up to 24 months after termination of pregnancy (currently 6 months). The Department of Agriculture must submit a report to Congress evaluating the effect of these changes to the program on (1) maternal and infant health outcomes, (2) breastfeeding rates, and (3) qualitative evaluations of family experiences under WIC. 

Bill· HRH.R. 7973 (119th)referred

Momnibus Act

United States · United States Congress · 18 March 2026

Bill· HRH.R. 7802 (119th)referred

DISCLOSE Act of 2026

United States · United States Congress · 4 March 2026

Democracy Is Strengthened by Casting Light On Spending in Elections Act of 2026 or the DISCLOSE Act of 2026 This bill addresses campaign finance, including by expanding the prohibition on campaign spending by foreign nationals, requiring additional disclosures of campaign expenditures, and requiring additional disclosures regarding certain political advertisements. Specifically, the bill expands existing foreign money prohibitions to include disbursements for paid web-based or digital communications and federal judicial nomination communications. It also prohibits foreign nationals from contributing to campaigns related to ballot initiatives and referenda. The Government Accountability Office must, for each four-year election cycle, study and report on the incidence of illicit foreign money in federal elections. Next, the bill makes it unlawful to establish or use a corporation, company, or other entity with the intent to conceal an election contribution or donation by a foreign national. A violator is subject to criminal penalties—a fine, a prison term of up to five years, or both. Covered organizations (e.g., corporations, labor organizations, and political organizations) must, within 24 hours, file reports with the Federal Election Commission to disclose campaign expenditures of more than $10,000 during an election cycle. The bill also requires organizations to provide additional disclosures regarding political advertisements, including the donors who contributed the most money to that organization in the last year.